Journal article icon

Journal article

Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): Study protocol for a randomized controlled pilot trial

Abstract:

Background: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this condition. The use of low-dose spironolactone has previously been shown to improve arterial stiffness and reduce left ventricular mass safely in early-stage chronic kidney disease in the context of careful monitoring at a university hospital. However, the majority of...

Expand abstract

Actions


Access Document


Publisher copy:
10.1186/1745-6215-15-158

Authors


Publisher:
BioMed Central
Journal:
Trials More from this journal
Volume:
15
Issue:
1
Publication date:
2014-05-06
DOI:
EISSN:
1745-6215
Language:
English
Keywords:
Pubs id:
pubs:467082
UUID:
uuid:aaeb2d91-0c21-4fe3-a54a-7b071625d8c2
Local pid:
pubs:467082
Source identifiers:
467082
Deposit date:
2014-06-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP